70005-89-9

Basic information

• Product Name: (4R)-4-(2-HYDROXYETHYL)-2,2-DIMETHYL-1,3-DIOXOLANE
• Synonyms: (R)-1,2-ISOPROPYLIDENEBUTANE-1,2,4-TRIOL;2(2,2-DIMETHYL-[1,3] DIOXOLAN-4-YL)-ETHANOL (R);(4R)-4-(2-HYDROXYETHYL)-2,2-DIMETHYL-1,3-DIOXOLANE;(4R)-4-(2-HYDROXYETHYL)-2,2-DIMETHYL-1,&;(R)-2-(2,2-Dimethyl-1,3-dioxolan-4-yl)ethanol;(R)-4-(2-Hydroxyethyl)-2,2-dimethyl-1,3-dioxolane;(R)-2,2-DIMETHYL-4-HYDROXYETHYL-[1,3]DIOXOLANE;(4R)-4-(2-Hydroxyethyl)-2,2-dimethyl-1,3-dioxolane 96%
• CAS NO: 70005-89-9
• Molecular Formula: C₇H₁₄O₃
• Molecular Weight: 146.18
• Product Categories: Chiral Building Blocks;Dioxanes & Dioxolanes;Dioxolanes;Glycidyl Compounds, etc. (Chiral);Synthetic Organic Chemistry;Alcohols;Chiral Building Blocks;Organic Building Blocks
• Mol File: 70005-89-9.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 207 °C(lit.)
• Flash Point: 224 °F
• Appearance: /
• Density: 1.045 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0771mmHg at 25°C
• Refractive Index: n20/D 1.4390(lit.)
• PKA: 14.80±0.10(Predicted)
• CAS DataBase Reference: (4R)-4-(2-HYDROXYETHYL)-2,2-DIMETHYL-1,3-DIOXOLANE(CAS DataBase Reference)
• NIST Chemistry Reference: (4R)-4-(2-HYDROXYETHYL)-2,2-DIMETHYL-1,3-DIOXOLANE(70005-89-9)
• EPA Substance Registry System: (4R)-4-(2-HYDROXYETHYL)-2,2-DIMETHYL-1,3-DIOXOLANE(70005-89-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 70005-89-9(Hazardous Substances Data)

Usage

Uses

(4R)-4-(2-Hydroxyethyl)-2,2-dimethyl-1,3-dioxolane can be used:To introduce a chiral center selectively in the carbon chain C10 during the total synthesis of protectin D1.As a starting material in the total synthesis of an anti-diabetic molecule cytopiloyne.As a starting material in the preparation of 4-15N-amino-2-butane-1,2-diol, which is used to synthesize 15N-labeled oligodeoxynucleotides.

InChI:InChI=1/C7H14O3/c1-7(2)9-5-6(10-7)3-4-8/h6,8H,3-5H2,1-2H3/t6-/m1/s1

Upstream product

• 97-67-6 L-malic acid 
• 67-64-1 acetone 
• 115114-86-8 3,4-O-isopropylidene-L-(S)-erythrulose 
• 92973-40-5 methyl (2R,3S)-3,4-O-isopropylidene-2,3,4-trihydroxybutanoate 
• 116556-67-3 Methyl 3,4-O-isopropylidene-2-O-phenoxythiocarbonyl-L-threonate 
• 126946-55-2 ethyl (2rac,3S)-3,4-O-isopropylidene-2-chloro-3,4-dihydroxybutane 
• 114185-07-8 ethyl (2R)-2-[(1S)-3,3-dimethyl(2,4-dioxolanyl)]-2-hydroxyacetate 
• 126946-53-0 ethyl (2R,3S)-3,4-O-isopropylidene-2-p-toluenesulfonyl-3,4-dihydroxybutanoate 
• 91274-05-4 (2S,3S)-1,2-O-isopropylidene-1,2,3,4-tetrol 
• 93367-10-3 (2S,3S)-3,4-epoxy-1,2-di-O-isopropylidenebutane-1,2-diol 
• 192506-32-4 t-butyl (2R,4R)-4,5-isopropylidenedioxy-2-(methylamino)pentanoate 
• 909726-01-8 (2R,4R)-1,2-O-isopropylidene-4-(methylamino)pentane-1,2,5-triol 
• 322765-15-1 (E)-ethyl 4-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)but-2-enoate 
• 159517-86-9 (R)-(+)-4-(2-benzyloxyethyl)-2,2-dimethyl-1,3-dioxolane 

Downstream Products

• 1196989-23-7 5-({2-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]ethyl}sulfanyl)-1-phenyl-1H-tetrazole 
• 1143519-52-1 rac-[(4S*,5R*)-2-(2-tert-butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dimethyl-4,5-dihydro-imidazol-1-yl]-{4-[2-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-ethyl]-piperazin-1-yl}-methanone 
• 1361105-46-5 (R)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl 2,4,6-triisopropylbenzoate 
• 1084333-30-1 2-[2-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-ethoxy]-4,6-difluoro-benzonitrile 
• 114828-16-9 Benzyl-[(E)-(S)-4-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-1-methyl-but-2-enyl]-carbamic acid benzyl ester 
• 114828-14-7 Benzyl-[(Z)-(S)-4-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-1-methyl-but-2-enyl]-carbamic acid benzyl ester 
• 114884-42-3 (4S,5S)-3-Benzyl-5-[(R)-2-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-1-iodo-ethyl]-4-methyl-oxazolidin-2-one 
• 114828-15-8 (4S,5R)-3-Benzyl-5-[(R)-2-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-1-iodo-ethyl]-4-methyl-oxazolidin-2-one 
• 114884-41-2 (4S,5R)-3-Benzyl-5-[(S)-2-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-1-iodo-ethyl]-4-methyl-oxazolidin-2-one 
• 114828-13-6 [(Z)-(S)-4-((S)-2,2-Dimethyl-[1,3]dioxolan-4-yl)-1-methyl-but-2-enyl]-carbamic acid benzyl ester 

Relevant articles and documents

Cobalt versus Osmium: Control of Both trans and cis Selectivity in Construction of the EFG Rings of Pectenotoxin 4

Catalytic oxidative cyclisation reactions have been employed for the synthesis of the E and F rings of the complex natural product target pectenotoxin 4. The choice of metal catalyst (cobalt- or osmium-based) allowed for the formation of THF rings with either trans or cis stereoselectivity. Fragment union using a modified Julia reaction then enabled the synthesis of an advanced synthetic intermediate containing the EF and G rings of the target.

Total synthesis of phorboxazole A via de novo oxazole formation: Strategy and component assembly

The phorboxazole natural products are among the most potent inhibitors of cancer cell division, but they are essentially unavailable from natural sources at present. Laboratory syntheses based upon tri-component fragment coupling strategies have been developed that provide phorboxazole A and analogues in a reliable manner and with unprecedented efficiency. This has been orchestrated to occur via the sequential or simultaneous formation of both of the natural product's oxazole moieties from two serine-derived amides, involving oxidation-cyclodehydrations. The optimized preparation of three pre-assembled components, representing carbons 3-17, 18-30, and 31-46, has been developed. This article details the design and syntheses of these three essential building blocks. The convergent coupling approach is designed to facilitate the incorporation of structural changes within each component to generate unnatural analogues, targeting those with enhanced therapeutic potential and efficacy.

Benzimidazole compound

An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.